CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
By L. G. Almeida, N. Sakabe, A. R. Oliveira, M. Silva, Alex S. Mundstein, T. Cohen, Yao-Tseng Chen, R. Chua, S. Gurung, S. Gnjatic and 9 more. Nucleic Acids Res., 2008
411 citations recorded by the source corpus.
The potency of the immune response has still to be harnessed effectively to combat human cancers. However, the discovery of T-cell targets in melanomas and other tumors has raised the possibility that cancer vaccines can be used to induce a therapeutically effective immune response against cancer. The targets, cancer-testis (CT) antigens, are immunogenic proteins preferentially expressed in normal gametogenic tissues and different histological types of tumors. Therapeutic cancer vaccines directed against CT antigens are currently in late-stage clinical trials testing whether they can delay or prevent recurrence of lung cancer and melanoma following surgical removal of primary tumors. CT antigens constitute a large, but ill-defined, family of proteins that exhibit a remarkably restricted expression. Currently, there is a considerable amount of information about these proteins, but the data are scattered through the literature and in several bioinformatic databases. The database presented here, CTdatabase (http://www.cta.lncc.br), unifies this knowledge to facilitate both the mining of the existing deluge of data, and the identification of proteins alleged to be CT antigens, but that do not have their characteristic restricted expression pattern. CTdatabase is more than a repository of CT antigen data, since all the available information was carefully curated and annotated with most data being specifically processed for CT antigens and stored locally. Starting from a compilation of known CT antigens, CTdatabase provides basic information including gene names and aliases, RefSeq accession numbers, genomic location, known splicing variants, gene duplications and additional family members. Gene expression at the mRNA level in normal and tumor tissues has been collated from publicly available data obtained by several different technologies. Manually curated data related to mRNA and protein expression, and antigen-specific immune responses in cancer patients are also available, together with links to PubMed for relevant CT antigen articles.
Subfields: Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/c5baf002b1e2d3535e4270ef56e18dc1168a8ec7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
- M. Berdasco
- Zlatko Trajanoski
- Catherine J. Wu
- Mirjana Efremova
- Manel Esteller
- Nir Hacohen
- Michael S. Rooney
- Yi Zhang
Citations in the corpus
- Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade (2016, methodology): “Cancer-germline antigens The list of cancer germline antigens (CGA) was extracted from the Cancer-Testis database (Almeida et al., 2009) (Supplementary Table S2).”
- Aberrant epigenetic landscape in cancer: how cellular identity goes awry. (2010, background): “, 1999), but these CG genes are expressed in histologically distinct types of malignant human tumors and transcriptional activation is correlated with hypomethylation (Weber et al., 2007; Almeida et al., 2009).”
- Molecular and genetic properties of tumors associated with local immune cytolytic activity (2015, positive): “Using a set of 276 known CT genes (Almeida et al., 2009), we used GTEx to identify a subset of 60 that are transcriptionally silent in normal non-germline tissues.”